Table 1. Characteristics of thymic MALT lymphoma and amyloidosis.
| Thymic tumor | Case No. | Age | Gender | Coexistent AD | Age at diagnosis of AD | Treatment of AD | Tumor detection | Tumor size (mm) | CT findings of tumor | SUVmax | Amyloid protein | Treatment | Follow up period (days) | Prognosis | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| calcification | cystic lesion | ||||||||||||||
| Amyloidosis | 1 | 71 | F | SjS | 50 | None | Medical checkup | 100 | (+) | (+) | 5.9 | AL | Total thymectomy | 449 | Alive with no recurrence |
| MALT lymphoma with amyloid deposition | 2 | 49 | F | SjS | 49 | None | Medical checkup | 120 | (+) | (+) | NE | AL | Total thymectomy | 1,918 | Alive with no recurrence |
| 3 | 76 | M | SSc | 62 | Steroid | Medical checkup | 28 | (+) | (+) | 3.6 | AL | Total thymectomy | 424 | Alive with no recurrence | |
| MALT lymphoma | 4 | 66 | F | SjS | 66 | None | Screening for cough | 20 | (–) | (–) | NE | NE | Total thymectomy | 1,957 | Alive with no recurrence |
| 5 | 38 | F | SjS | 36 | None | sIL-2R antibody | 70 | (–) | (–) | 5.8 | NE | Total thymectomy | 1,747 | Alive with no recurrence | |
MALT, mucosa-associated lymphoid tissue; AD, autoimmune disease; SjS, Sjögren’ syndrome; SSc, Systemic sclerosis; sIL-2R, serum soluble interleukin-2 receptor; SUVmax, maximum standard uptake value; AL, amyloidogenic light chain; NE, Not examined; AIS, adenocarcinoma in situ.